01:35:17 EST Thu 22 Feb 2024
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:AZN - ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS - http://www.astrazeneca.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AZN - Q0.265.09·65.500.165.09+0.050.15,402.4345,98231,77464.38  65.09  64.2276.56  60.4719:55:47Feb 1915 min RT 2¢

Recent Trades - Last 10 of 31774
Time ETExPriceChangeVolume
19:55:47Q65.490.4525
19:55:25Q65.490.4528
19:55:24Q65.480.4416
19:53:10Q65.090.056
19:52:28Q65.490.4553
19:52:26Q65.400.361
19:45:59Q65.290.251
19:22:50Q65.290.251
19:02:03Q65.190.1520
18:47:20Q65.080.043

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-02-19 07:10U:AZNNews ReleaseDatopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
2024-02-19 07:05U:AZNNews ReleaseTAGRISSO ‚ ® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
2024-02-19 02:00U:AZNNews ReleaseDatopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
2024-02-16 22:00U:AZNNews ReleaseTAGRISSO ‚ ® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
2024-02-08 02:03U:AZNNews ReleaseAstraZeneca Full year and Q4 2023 Financial Results
2024-02-07 06:51U:AZNNews ReleaseSOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain
2024-02-06 09:00U:AZNNews ReleaseAstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development
2024-02-05 09:00U:AZNNews ReleaseYiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach
2024-01-29 07:00U:AZNNews ReleaseENHERTU ‚ ® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors